Lifecore Biomedical, Inc. (LFCR)
USD 5.81
(1.57%)
USD 5.81
(1.57%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 121.89 Million USD | 30.16% |
| 2023 | 93.64 Million USD | -38.16% |
| 2022 | 151.44 Million USD | -31.19% |
| 2021 | 220.1 Million USD | -0.29% |
| 2020 | 220.75 Million USD | 45.78% |
| 2019 | 151.43 Million USD | 116.21% |
| 2018 | 70.04 Million USD | 44.24% |
| 2017 | 48.56 Million USD | -6.74% |
| 2016 | 52.07 Million USD | 83.4% |
| 2015 | 28.39 Million USD | 41.05% |
| 2014 | 20.12 Million USD | -34.19% |
| 2013 | 30.58 Million USD | -16.9% |
| 2012 | 36.8 Million USD | 214.72% |
| 2011 | 11.69 Million USD | 388.98% |
| 2010 | -4.04 Million USD | 90.69% |
| 2009 | -43.45 Million USD | 2.11% |
| 2008 | -44.39 Million USD | 29.0% |
| 2007 | -62.52 Million USD | -237.97% |
| 2006 | -18.5 Million USD | -89.11% |
| 2005 | -9.78 Million USD | -485.46% |
| 2004 | 2.53 Million USD | -74.09% |
| 2003 | 9.79 Million USD | 1.04% |
| 2002 | 9.69 Million USD | -60.79% |
| 2001 | 24.72 Million USD | 22.17% |
| 2000 | 20.23 Million USD | 4147.0% |
| 1999 | -500 Thousand USD | 92.06% |
| 1998 | -6.3 Million USD | -21.15% |
| 1997 | -5.2 Million USD | 62.04% |
| 1996 | -13.7 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 FY | 121.89 Million USD | 30.16% |
| 2024 Q2 | 117.04 Million USD | 6.46% |
| 2024 Q4 | 121.89 Million USD | -1.05% |
| 2024 Q3 | 123.19 Million USD | 5.26% |
| 2024 Q1 | 109.94 Million USD | 17.4% |
| 2023 Q4 | 93.64 Million USD | -24.47% |
| 2023 FY | 93.64 Million USD | -38.16% |
| 2023 Q1 | 152.81 Million USD | 0.84% |
| 2023 Q2 | 154.13 Million USD | 0.86% |
| 2023 Q3 | 123.98 Million USD | -19.56% |
| 2022 Q1 | 175.51 Million USD | -20.26% |
| 2022 Q3 | 133.03 Million USD | -27.02% |
| 2022 Q4 | 151.54 Million USD | 13.92% |
| 2022 Q2 | 182.29 Million USD | 3.86% |
| 2022 FY | 151.44 Million USD | -31.19% |
| 2021 Q3 | 212.26 Million USD | 9.59% |
| 2021 FY | 220.1 Million USD | -0.29% |
| 2021 Q1 | 200.37 Million USD | -9.23% |
| 2021 Q2 | 193.68 Million USD | -3.34% |
| 2021 Q4 | 220.1 Million USD | 3.7% |
| 2020 Q2 | 213.87 Million USD | 8.69% |
| 2020 FY | 220.75 Million USD | 45.78% |
| 2020 Q4 | 220.75 Million USD | 8.85% |
| 2020 Q3 | 202.81 Million USD | -5.17% |
| 2020 Q1 | 196.77 Million USD | 29.94% |
| 2019 FY | 151.43 Million USD | 116.21% |
| 2019 Q1 | 82.32 Million USD | 17.53% |
| 2019 Q2 | 83.9 Million USD | 1.92% |
| 2019 Q4 | 151.43 Million USD | 4.25% |
| 2019 Q3 | 145.26 Million USD | 73.14% |
| 2018 Q2 | 54.08 Million USD | 3.97% |
| 2018 Q1 | 52.02 Million USD | 7.13% |
| 2018 Q4 | 70.04 Million USD | 35.87% |
| 2018 FY | 70.04 Million USD | 44.24% |
| 2018 Q3 | 51.55 Million USD | -4.69% |
| 2017 Q2 | 52.41 Million USD | 11.15% |
| 2017 Q1 | 47.15 Million USD | -9.44% |
| 2017 Q4 | 48.56 Million USD | 22.97% |
| 2017 FY | 48.56 Million USD | -6.74% |
| 2017 Q3 | 39.49 Million USD | -24.66% |
| 2016 FY | 52.07 Million USD | 83.4% |
| 2016 Q2 | 42.23 Million USD | 26.08% |
| 2016 Q1 | 33.5 Million USD | 17.99% |
| 2016 Q3 | 52.65 Million USD | 24.65% |
| 2016 Q4 | 52.07 Million USD | -1.1% |
| 2015 Q1 | 31.5 Million USD | 56.5% |
| 2015 Q4 | 28.39 Million USD | -16.73% |
| 2015 Q2 | 42.25 Million USD | 34.13% |
| 2015 FY | 28.39 Million USD | 41.05% |
| 2015 Q3 | 34.09 Million USD | -19.31% |
| 2014 Q4 | 20.12 Million USD | -11.69% |
| 2014 Q3 | 22.79 Million USD | -29.68% |
| 2014 FY | 20.12 Million USD | -34.19% |
| 2014 Q2 | 32.41 Million USD | 4.3% |
| 2014 Q1 | 31.07 Million USD | 1.6% |
| 2013 Q3 | 36.89 Million USD | -21.28% |
| 2013 Q2 | 46.87 Million USD | 8.0% |
| 2013 Q1 | 43.39 Million USD | 17.91% |
| 2013 FY | 30.58 Million USD | -16.9% |
| 2013 Q4 | 30.58 Million USD | -17.1% |
| 2012 Q1 | 11.58 Million USD | -0.91% |
| 2012 Q3 | 3.96 Million USD | -70.1% |
| 2012 Q4 | 36.8 Million USD | 828.04% |
| 2012 FY | 36.8 Million USD | 214.72% |
| 2012 Q2 | 13.26 Million USD | 14.47% |
| 2011 Q2 | 16.38 Million USD | 23.58% |
| 2011 Q3 | 14.15 Million USD | -13.62% |
| 2011 FY | 11.69 Million USD | 388.98% |
| 2011 Q4 | 11.69 Million USD | -17.36% |
| 2011 Q1 | 13.25 Million USD | 427.58% |
| 2010 Q3 | -6.33 Million USD | -185.28% |
| 2010 Q1 | -3.99 Million USD | 90.8% |
| 2010 FY | -4.04 Million USD | 90.69% |
| 2010 Q2 | -2.22 Million USD | 44.42% |
| 2010 Q4 | -4.04 Million USD | 36.16% |
| 2009 Q3 | -47.27 Million USD | -11.64% |
| 2009 Q2 | -42.34 Million USD | 7.44% |
| 2009 Q4 | -43.45 Million USD | 8.07% |
| 2009 FY | -43.45 Million USD | 2.11% |
| 2009 Q1 | -45.74 Million USD | -3.04% |
| 2008 FY | -44.39 Million USD | 29.0% |
| 2008 Q1 | -46.01 Million USD | 26.4% |
| 2008 Q2 | -44.97 Million USD | 2.27% |
| 2008 Q4 | -44.39 Million USD | 19.43% |
| 2008 Q3 | -55.1 Million USD | -22.53% |
| 2007 Q4 | -62.52 Million USD | -7.32% |
| 2007 Q2 | -11.71 Million USD | 18.2% |
| 2007 FY | -62.52 Million USD | -237.97% |
| 2007 Q3 | -58.26 Million USD | -397.47% |
| 2007 Q1 | -14.31 Million USD | 22.61% |
| 2006 Q3 | -17.99 Million USD | -706.98% |
| 2006 Q2 | 2.96 Million USD | 147.0% |
| 2006 FY | -18.5 Million USD | -89.11% |
| 2006 Q4 | -18.5 Million USD | -2.83% |
| 2006 Q1 | -6.3 Million USD | 35.54% |
| 2005 Q1 | 3.89 Million USD | 53.55% |
| 2005 FY | -9.78 Million USD | -485.46% |
| 2005 Q4 | -9.78 Million USD | 9.53% |
| 2005 Q3 | -10.81 Million USD | -519.8% |
| 2005 Q2 | 2.57 Million USD | -33.9% |
| 2004 Q1 | 8.51 Million USD | -19.34% |
| 2004 FY | 2.53 Million USD | -74.09% |
| 2004 Q3 | 3.93 Million USD | -75.2% |
| 2004 Q2 | 15.87 Million USD | 86.39% |
| 2004 Q4 | 2.53 Million USD | -35.53% |
| 2003 Q4 | 10.56 Million USD | 17.71% |
| 2003 FY | 9.79 Million USD | 1.04% |
| 2003 Q3 | 8.97 Million USD | -7.45% |
| 2003 Q2 | 9.69 Million USD | -39.38% |
| 2003 Q1 | 15.99 Million USD | 9.75% |
| 2002 FY | 9.69 Million USD | -60.79% |
| 2002 Q2 | 24.72 Million USD | -24.36% |
| 2002 Q3 | 16.63 Million USD | -32.71% |
| 2002 Q1 | 32.68 Million USD | 12.37% |
| 2002 Q4 | 14.57 Million USD | -12.41% |
| 2001 Q1 | 21.3 Million USD | 37.97% |
| 2001 FY | 24.72 Million USD | 22.17% |
| 2001 Q4 | 29.08 Million USD | 8.16% |
| 2001 Q2 | 20.23 Million USD | -5.03% |
| 2001 Q3 | 26.89 Million USD | 32.89% |
| 2000 Q1 | -1.6 Million USD | 65.96% |
| 2000 FY | 20.23 Million USD | 4147.0% |
| 2000 Q3 | 18.3 Million USD | 3760.0% |
| 2000 Q2 | -500 Thousand USD | 68.75% |
| 2000 Q4 | 15.44 Million USD | -15.62% |
| 1999 Q3 | -6.2 Million USD | 1.59% |
| 1999 Q4 | -4.7 Million USD | 24.19% |
| 1999 Q1 | -6 Million USD | 44.95% |
| 1999 Q2 | -6.3 Million USD | -5.0% |
| 1999 FY | -500 Thousand USD | 92.06% |
| 1998 Q2 | -5.2 Million USD | 28.77% |
| 1998 Q4 | -10.9 Million USD | 5.22% |
| 1998 Q3 | -11.5 Million USD | -121.15% |
| 1998 FY | -6.3 Million USD | -21.15% |
| 1998 Q1 | -7.3 Million USD | -386.67% |
| 1997 Q3 | -9.9 Million USD | 27.74% |
| 1997 Q1 | -13 Million USD | 33.67% |
| 1997 Q2 | -13.7 Million USD | -5.38% |
| 1997 Q4 | -1.5 Million USD | 84.85% |
| 1997 FY | -5.2 Million USD | 62.04% |
| 1996 Q4 | -19.6 Million USD | 0.0% |
| 1996 FY | -13.7 Million USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bright Green Corporation | 1.84 Million USD | -6518.69% |
| Alpha Teknova, Inc. | 1.97 Million USD | -6075.177% |
| ANI Pharmaceuticals, Inc. | 94.2 Million USD | -29.394% |
| Aquestive Therapeutics, Inc. | 74.95 Million USD | -62.639% |
| Collegium Pharmaceutical, Inc. | 435.33 Million USD | 71.999% |
| Cosmos Health Inc. | 8.59 Million USD | -1318.944% |
| Journey Medical Corporation | -9.7 Million USD | 1355.516% |
| Embecta Corp. | 1.31 Billion USD | 90.709% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 73.425% |
| Dynavax Technologies Corporation | 106.63 Million USD | -14.313% |
| Intra-Cellular Therapies, Inc. | -130.82 Million USD | 193.174% |
| Pacira BioSciences, Inc. | 432.74 Million USD | 71.832% |
| PainReform Ltd. | -7.95 Million USD | 1633.308% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 879.666% |
| Sunshine Biopharma, Inc. | -15.63 Million USD | 879.666% |
| SCYNEXIS, Inc. | -19.35 Million USD | 729.964% |
| Safety Shot Inc | -2.28 Million USD | 5436.164% |
| China SXT Pharmaceuticals, Inc. | -9.42 Million USD | 1392.698% |
| Procaps Group, S.A. | 242.93 Million USD | 49.822% |
| Theratechnologies Inc. | 24.87 Million USD | -390.121% |
| Harrow Health, Inc. | 116.41 Million USD | -4.708% |
| Sonoma Pharmaceuticals, Inc. | -2.52 Million USD | 4937.222% |
| Biofrontera Inc. | 4.05 Million USD | -2905.375% |
| DURECT Corporation | -7.65 Million USD | 1692.605% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 463.582% |
| Cronos Group Inc. | -663.32 Million USD | 118.377% |
| OptiNose, Inc. | 58.06 Million USD | -109.934% |
| Ironwood Pharmaceuticals, Inc. | 623.38 Million USD | 80.446% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 936.522% |
| RedHill Biopharma Ltd. | -5.18 Million USD | 2450.507% |
| Organogenesis Holdings Inc. | 15.01 Million USD | -711.95% |
| Guardion Health Sciences, Inc. | -6.35 Million USD | 2016.742% |
| Cumberland Pharmaceuticals Inc. | 106.85 Thousand USD | -113973.686% |
| Radius Health, Inc. | 359.28 Million USD | 66.072% |
| Universe Pharmaceuticals INC | 197.2 Thousand USD | -61711.581% |
| ProPhase Labs, Inc. | 19.23 Million USD | -533.862% |
| Phibro Animal Health Corporation | 454.84 Million USD | 73.2% |
| Procaps Group S.A. | 242.93 Million USD | 49.822% |
| Alvotech | 1.06 Billion USD | 88.547% |
| TherapeuticsMD, Inc. | 3.67 Million USD | -3214.247% |
| Viatris Inc. | 17.13 Billion USD | 99.288% |
| Rockwell Medical, Inc. | 4.45 Million USD | -2635.592% |
| Aytu BioPharma, Inc. | -4.87 Million USD | 2599.446% |
| SIGA Technologies, Inc. | -148.68 Million USD | 181.986% |
| Tilray Brands, Inc. | 158.97 Million USD | 23.323% |
| Shineco, Inc. | 29.29 Million USD | -316.172% |
| PetIQ, Inc. | 351.93 Million USD | 65.363% |
| Regencell Bioscience Holdings Limited | -2.9 Million USD | 4301.311% |
| Incannex Healthcare Limited | -5.48 Million USD | 2322.388% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 31.248% |
| Alimera Sciences, Inc. | 55.3 Million USD | -120.395% |
| Silver Spike Investment Corp. | -32.61 Million USD | 473.787% |
| Assertio Holdings, Inc. | -32.52 Million USD | 474.736% |
| Shuttle Pharmaceuticals Holdings, Inc. | -1.48 Million USD | 8288.097% |
| Petros Pharmaceuticals, Inc. | -5.06 Million USD | 2508.869% |
| Clever Leaves Holdings Inc. | -4.81 Million USD | 2632.156% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 1584.122% |
| Avadel Pharmaceuticals plc | 4.21 Million USD | -2790.633% |
| Hempacco Co., Inc. | 13.61 Million USD | -795.342% |
| Talphera, Inc. | -5.72 Million USD | 2230.711% |
| Alvotech | 1.06 Billion USD | 88.547% |
| Eagle Pharmaceuticals, Inc. | 7.14 Million USD | -1606.06% |
| Lantheus Holdings, Inc. | -96.71 Million USD | 226.045% |
| Currenc Group, Inc. | -16.57 Million USD | 835.516% |
| Kamada Ltd. | -46.43 Million USD | 362.533% |
| Indivior PLC | -33.95 Million USD | 459.03% |
| Evoke Pharma, Inc. | 260.57 Thousand USD | -46680.569% |
| Flora Growth Corp. | -713 Thousand USD | 17196.494% |
| Cyclo Therapeutics, Inc. | -8.21 Million USD | 1584.122% |
| Evolus, Inc. | 63.7 Million USD | -91.339% |
| HUTCHMED (China) Limited | -197.45 Million USD | 161.734% |
| Amphastar Pharmaceuticals, Inc. | 479.11 Million USD | 74.557% |
| Akanda Corp. | 3.9 Million USD | -3021.655% |